See more : The Company for Cooperative Insurance (8010.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Nova Mentis Life Science Corp. (NMLSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nova Mentis Life Science Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NOS, S.G.P.S., S.A. (NOS.LS) Income Statement Analysis – Financial Results
- Unipar Carbocloro S.A. (UNIP6.SA) Income Statement Analysis – Financial Results
- GL Events SA (GLO.PA) Income Statement Analysis – Financial Results
- Uniparts India Limited (UNIPARTS.BO) Income Statement Analysis – Financial Results
- Jiangsu Yoke Technology Co., Ltd. (002409.SZ) Income Statement Analysis – Financial Results
Nova Mentis Life Science Corp. (NMLSF)
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.41K | 0.00 | 0.00 | 11.47K | 7.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.00 |
| Cost of Revenue | 0.00 | 3.79K | 5.00K | 9.74K | 5.57K | 8.65K | 3.02K | 588.00 | 641.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 25.41K | -3.79K | -5.00K | 1.73K | 1.63K | -8.65K | -3.02K | -588.00 | -641.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 15.07% | 22.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 71.15K | 115.16K | 860.07K | 31.32K | 0.00 | 22.11K | 93.87K | 724.74K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 857.77K | 1.82M | 2.07M | 1.77M | 1.21M | 3.53M | 1.70M | 1.24M | 703.91K | 490.46K | 186.99K | 650.74K | 895.22K | 646.75K | 1.64M | 705.25K | 0.00 | 100.03K | 0.00 |
| Selling & Marketing | 273.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.22K | 76.52K | 6.29K | 0.00 | 0.00 | 0.00 | 1.69K | 0.00 |
| SG&A | 1.13M | 1.82M | 2.07M | 1.77M | 1.21M | 3.53M | 1.70M | 1.24M | 703.91K | 490.46K | 186.99K | 654.95K | 971.74K | 653.03K | 1.64M | 705.25K | 614.19K | 101.72K | 62.73K |
| Other Expenses | 0.00 | 7.69K | 0.00 | 19.43K | 0.00 | -15.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.20M | 1.94M | 2.93M | 1.80M | 1.22M | 3.56M | 1.80M | 1.96M | 704.55K | 491.18K | 188.87K | 659.69K | 986.93K | 698.69K | 1.84M | 752.80K | 614.19K | 101.72K | 62.73K |
| Cost & Expenses | 1.20M | 1.94M | 2.93M | 1.81M | 1.23M | 3.56M | 1.80M | 1.96M | 704.55K | 491.18K | 188.87K | 659.69K | 986.93K | 698.69K | 1.84M | 752.80K | 614.19K | 101.72K | 62.73K |
| Interest Income | 2.00 | 230.08K | 97.62K | 4.12K | 20.75K | 14.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00 | 59.00 | 7.48K | 13.33K | 3.08K | 488.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 1.69K | 2.21K | 16.80K | 1.52K | 595.00 | 2.07K | 323.00 |
| Depreciation & Amortization | 2.94K | 3.79K | 5.00K | 6.82K | 9.80K | 8.65K | 3.02K | 588.00 | 641.00 | 720.00 | 1.87K | 4.73K | 9.99K | 5.70K | 1.83K | 1.13K | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.20M | -1.84M | -2.80M | -1.79M | -1.11M | -3.31M | -1.58M | -1.88M | -652.66K | -453.37K | -112.57K | -654.95K | -976.93K | -692.98K | -1.84M | -744.19K | -614.19K | -101.72K | -62.24K |
| EBITDA Ratio | -4,732.53% | 0.00% | 0.00% | 171,516.34% | -15,428.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,754.10% |
| Operating Income | -1.20M | -1.17M | -3.09M | 19.67M | -1.12M | -3.66M | -1.73M | -1.96M | -704.55K | -491.18K | -188.87K | -659.69K | -986.93K | -698.69K | -1.86M | -754.31K | -614.19K | -101.72K | -62.24K |
| Operating Income Ratio | -4,732.53% | 0.00% | 0.00% | 171,456.90% | -15,564.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,754.10% |
| Total Other Income/Expenses | -22.12K | -624.18K | 113.78K | -21.45M | -278.66K | -259.93K | -281.83K | -197.34K | 19.10K | -1.57M | -98.54K | -5.94M | -2.33M | -1.96M | 59.00 | 7.48K | 12.74K | 202.43K | 0.00 |
| Income Before Tax | -1.22M | -2.47M | -2.68M | -23.25M | -1.40M | -3.57M | -1.87M | -2.08M | -685.45K | -2.06M | -263.29K | -6.60M | -3.31M | -2.66M | -1.86M | -746.84K | -601.45K | 100.71K | 0.00 |
| Income Before Tax Ratio | -4,819.61% | 0.00% | 0.00% | -202,658.54% | -19,439.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 536.30K | -249.46K | 21.47M | 81.98K | -113.80K | 66.05K | 113.71K | 3.70K | -3.70K | 74.43K | 2.29K | 1.69K | -123.75K | -75.45K | -241.15K | -85.30K | -13.31K | 62.56K |
| Net Income | -1.22M | -2.47M | -2.68M | -23.25M | -1.40M | -3.57M | -1.87M | -2.08M | -689.15K | -2.06M | -263.29K | -6.60M | -3.31M | -2.54M | -1.78M | -505.68K | -516.15K | -87.40K | -62.56K |
| Net Income Ratio | -4,819.61% | 0.00% | 0.00% | -202,658.54% | -19,439.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,820.29% |
| EPS | -0.01 | -0.02 | -0.02 | -0.45 | 0.00 | -0.12 | -0.08 | -0.15 | -0.08 | -0.38 | -0.07 | -2.19 | -1.52 | -2.95 | -3.85 | -1.99 | -2.39 | -0.89 | -0.52 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.45 | 0.00 | -0.12 | -0.08 | -0.15 | -0.08 | -0.38 | -0.07 | -2.19 | -1.52 | -2.95 | -3.85 | -1.99 | -2.39 | -0.89 | -0.52 |
| Weighted Avg Shares Out | 146.78M | 136.56M | 111.10M | 51.15M | 3.20B | 29.59M | 22.28M | 13.80M | 8.91M | 5.41M | 3.64M | 3.02M | 2.18M | 860.51K | 462.84K | 254.05K | 216.09K | 97.98K | 120.00K |
| Weighted Avg Shares Out (Dil) | 146.76M | 136.56M | 111.10M | 51.15M | 3.20B | 29.59M | 22.28M | 13.80M | 8.91M | 5.41M | 3.64M | 3.02M | 2.18M | 860.51K | 462.84K | 254.05K | 216.09K | 97.98K | 120.00K |
Nova Mentis Assigns Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") is pleased to announce it has entered into an intellectual property conveyance agreement (the "Agreement") with...
CSE Bulletin: WITHDRAWN - Symbol Change - Inactive Designation - Nova Mentis Life Science Corp. (NOVA)
Toronto, Ontario--(Newsfile Corp. - le 8 août/August 2024) - Bulletin 2024-0809 - Symbol Change - Inactive Designation - Nova Mentis Life Science Corp. (NOVA) has been withdrawn. If you have any questions or require further information please contact Listings at...
CSE Bulletin: Symbol Change - Inactive Designation - Nova Mentis Life Science Corp. (NOVA)
Toronto, Ontario--(Newsfile Corp. - Le 8 août/August 2024) - The Exchange has determined that Nova Mentis Life Science Corp. (the “Issuer”) has not met the continued listing requirements as set out in CSE Policy 2, Appendix A, section 2A.6. Pursuant...
Nova Mentis Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024....
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders...
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders...
Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders,...
Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders...
Source: https://incomestatements.info
Category: Stock Reports